- Home
- MURA vs PMN Comparison
MURA vs PMN Comparison
Compare MURA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- PMN
- Stock Information
- Founded
- MURA 2013
- PMN 2004
- Country
- MURA Ireland
- PMN Canada
- Employees
- MURA N/A
- PMN N/A
- Industry
- MURA
- PMN Pharmaceuticals and Biotechnology
- Sector
- MURA
- PMN Health Care
- Exchange
- MURA Nasdaq
- PMN Nasdaq
- Market Cap
- MURA 17.7M
- PMN 18.8M
- IPO Year
- MURA N/A
- PMN N/A
- Fundamental
- Price
- MURA $2.63
- PMN $0.50
- Analyst Decision
- MURA Strong Buy
- PMN Strong Buy
- Analyst Count
- MURA 4
- PMN 1
- Target Price
- MURA $13.00
- PMN $6.00
- AVG Volume (30 Days)
- MURA 14.0M
- PMN 39.8K
- Earning Date
- MURA 05-20-2025
- PMN 05-20-2025
- Dividend Yield
- MURA N/A
- PMN N/A
- EPS Growth
- MURA N/A
- PMN N/A
- EPS
- MURA N/A
- PMN 0.11
- Revenue
- MURA N/A
- PMN N/A
- Revenue This Year
- MURA $34.35
- PMN N/A
- Revenue Next Year
- MURA N/A
- PMN N/A
- P/E Ratio
- MURA N/A
- PMN $4.69
- Revenue Growth
- MURA N/A
- PMN N/A
- 52 Week Low
- MURA $0.95
- PMN $0.51
- 52 Week High
- MURA $4.74
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- MURA 56.94
- PMN 35.83
- Support Level
- MURA $2.48
- PMN $0.47
- Resistance Level
- MURA $2.66
- PMN $0.60
- Average True Range (ATR)
- MURA 0.12
- PMN 0.07
- MACD
- MURA 0.04
- PMN -0.01
- Stochastic Oscillator
- MURA 42.58
- PMN 12.80
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.